AU2013306380A1 - Method for determining breast cancer treatment - Google Patents

Method for determining breast cancer treatment Download PDF

Info

Publication number
AU2013306380A1
AU2013306380A1 AU2013306380A AU2013306380A AU2013306380A1 AU 2013306380 A1 AU2013306380 A1 AU 2013306380A1 AU 2013306380 A AU2013306380 A AU 2013306380A AU 2013306380 A AU2013306380 A AU 2013306380A AU 2013306380 A1 AU2013306380 A1 AU 2013306380A1
Authority
AU
Australia
Prior art keywords
breast cancer
androgen
tissue sample
determining
enzalutamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013306380A
Other languages
English (en)
Inventor
Jennifer Richer Mouchantat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Colorado Springs
Original Assignee
University of Colorado System
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado System, University of Colorado Colorado Springs filed Critical University of Colorado System
Publication of AU2013306380A1 publication Critical patent/AU2013306380A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013306380A 2012-08-23 2013-03-15 Method for determining breast cancer treatment Abandoned AU2013306380A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261692331P 2012-08-23 2012-08-23
US61/692,331 2012-08-23
PCT/US2013/031812 WO2014031164A1 (en) 2012-08-23 2013-03-15 Method for determining breast cancer treatment

Publications (1)

Publication Number Publication Date
AU2013306380A1 true AU2013306380A1 (en) 2015-03-05

Family

ID=50150282

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013306380A Abandoned AU2013306380A1 (en) 2012-08-23 2013-03-15 Method for determining breast cancer treatment

Country Status (7)

Country Link
US (2) US10175240B2 (enExample)
EP (1) EP2888594B1 (enExample)
JP (1) JP6153613B2 (enExample)
AU (1) AU2013306380A1 (enExample)
CA (1) CA2882621A1 (enExample)
ES (1) ES2696202T3 (enExample)
WO (1) WO2014031164A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2739153T3 (en) 2011-07-29 2018-12-03 Medivation Prostate Therapeutics Llc TREATMENT OF BREAST CANCER
WO2014031164A1 (en) 2012-08-23 2014-02-27 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment
SG11201704425TA (en) 2014-12-12 2017-06-29 Medivation Prostate Therapeutics Inc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
KR102754524B1 (ko) * 2018-08-17 2025-01-13 제넨테크, 인크. 유방암 치료를 위한 진단 및 치료 방법들

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008185A (en) * 1985-11-04 1991-04-16 Cell Analysis Systems, Inc. Methods and apparatus for the quantitation of nuclear proteins
US5292638A (en) * 1990-12-07 1994-03-08 The Regents Of The University Of California Method of determining functional estrogen receptors for prognosis of cancer
IL152719A0 (en) * 2000-06-28 2003-06-24 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification
JP5078100B2 (ja) * 2006-04-18 2012-11-21 ウェルスタット バイオロジクス コーポレイション 循環癌細胞におけるステロイド受容体の検出および処置
CA2663595A1 (en) * 2006-08-07 2008-02-14 The Board Of Regents Of The University Of Texas System Proteomic patterns of cancer prognostic and predictive signatures
EP2065474A1 (en) * 2007-11-28 2009-06-03 Siemens Healthcare Diagnostics GmbH A method to assess prognosis and to predict therapeutic response to endocrine treatment
WO2009137543A2 (en) * 2008-05-06 2009-11-12 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment
WO2014031164A1 (en) 2012-08-23 2014-02-27 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment

Also Published As

Publication number Publication date
EP2888594A1 (en) 2015-07-01
EP2888594A4 (en) 2016-04-20
US10175240B2 (en) 2019-01-08
CA2882621A1 (en) 2014-02-27
WO2014031164A1 (en) 2014-02-27
ES2696202T3 (es) 2019-01-14
US20190113515A1 (en) 2019-04-18
JP2015529327A (ja) 2015-10-05
US20150253329A1 (en) 2015-09-10
US11221334B2 (en) 2022-01-11
JP6153613B2 (ja) 2017-06-28
EP2888594B1 (en) 2018-08-15

Similar Documents

Publication Publication Date Title
Cochrane et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
US11221334B2 (en) Method for determining breast cancer treatment
Tan et al. Tumor suppressor DRD2 facilitates M1 macrophages and restricts NF-κB signaling to trigger pyroptosis in breast cancer
Chia et al. A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer
Velpula et al. Glioma stem cell invasion through regulation of the interconnected ERK, integrin α6 and N-cadherin signaling pathway
Nickkho-Amiry et al. Peroxisome proliferator–activated receptors modulate proliferation and angiogenesis in human endometrial carcinoma
Barakat et al. CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells
Zarrinpashneh et al. Ablation of SGK1 impairs endothelial cell migration and tube formation leading to decreased neo-angiogenesis following myocardial infarction
WO2010096627A1 (en) Therapeutics and methods for treating neoplastic diseases comprising determining the level of caveolin-1 and/or caveolin-2 in a stromal cell sample
Abboud-Jarrous et al. Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL
EP2399129A1 (en) A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
Bilandzic et al. Betaglycan blocks metastatic behaviors in human granulosa cell tumors by suppressing NFκB-mediated induction of MMP2
Huang et al. Intracellular and extracellular S100A9 trigger epithelial-mesenchymal transition and promote the invasive phenotype of pituitary adenoma through activation of AKT1
Luo et al. Dynamic monitoring of GPER-mediated estrogenic effects in breast cancer associated fibroblasts: an alternative role of estrogen in mammary carcinoma development
Dotto et al. Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities
Cavalloni et al. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas
Eritja et al. Combinatorial therapy using dovitinib and ICI182. 780 (fulvestrant) blocks tumoral activity of endometrial cancer cells
Liang et al. Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells
US20250281509A1 (en) Sequential hormone therapy to improve survival and enhance response to immune therapy in men with prostate cancer
Zhang et al. Significance and mechanism of androgen receptor (AR) overexpression and AR-mTOR crosstalk in hepatocellular carcinoma
US20170336422A1 (en) Method for the detection of hormone sensitive disease progression
US8980571B2 (en) Method of identifying a candidate compound which may inhibit α9-nAchR overexpression or estrogen receptor-dependent transcription in nicotine-derived-compound-induced breast cancer cells
JP2013043862A (ja) 前立腺癌治療組成物及び前立腺癌治療組成物の有効成分のスクリーニング方法
KR102003449B1 (ko) 바이오마커로서 rbp2 및 이의 용도
Cheung P38 mitogen-activated protein kinase inhibition in castration-resistant prostate cancer

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted